Close
Novotech
Jabsco PureFlo 21 Single Use

Sharp completes first phase of $23 million investment in its Bethlehem clinical services facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Sharp – a part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has completed the first phase in the development of its new USD $23m state-of-the-art facility in Bethlehem, PA.

Sharp acquired the new Bethlehem facility for $14m in 2017 and has now completed a $2.5m relocation project, transferring the company’s clinical storage and distribution services from its Phoenixville site.

A second phase will see Sharp co-locate its fully integrated clinical services offering at the site when its packaging, manufacturing and analytical services move to the facility in late-2018, following a $6.4 million refit.

The Bethlehem development offers 1.5 million cubic feet of capacity on a 16-acre plot and will allow the company to increase pallet space for both cold and controlled-temperature storage by approximately 50%.

Frank Lis, president of Sharp Clinical Services, said: “The Bethlehem facility is a strategically important investment for Sharp. It will allow us to offer greater capacity, scalability and automation in response to growing demand for our services, as well as co-locating our clinical services at one facility.  

“This facility allows us to simultaneously support multiple large-scale phase III studies through to commercial launch.”
Investing in the Bethlehem site- has created 1.5 million cubic feet of new clinical services capacity in 2017 and is consistent with Sharp’s strategy of capacity expansion to support current clients and meet future demand.

ABOUT SHARP
Sharp, a division of UDG healthcare, is a global leader in contract packaging and clinical services. Operating from state-of-the-art facilities across the US and Europe, Sharp has built an international reputation for delivering cost-effective blister packaging, bottling, pouches and stick packs, compliance packaging, formulation and manufacturing services, label design and printing. Sharp is also a world leader in ’Track and Trace’ serialization services, which will require all prescription drugs to have a unique serial code for authentication and traceability.

For more information on Sharp and its solutions, visit www.sharpservices.com

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »